Clinical Trials on Melanoma in France

Total 406 results

Assistance Publique - Hôpitaux de Paris

Unknown

Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. (NILOMEL)

Stage IV Melanoma | Stage III Melanoma | Amplification | Malignant Skin Melanoma T0

France
Pierre Fabre Medicament
Biotrial

Active, not recruiting

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

Melanoma | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 Mutation

France
Pierre Fabre Medicament
Biotrial

Completed

Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

Melanoma | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 Mutation

France
CHU de Reims

Completed

Molecular Characterization of Advanced Stage Melanoma by Blood Sampling (MELCIRC)

Metastatic Melanoma

France
Nantes University Hospital
UMR892

Completed

Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study (MelSort)

Metastatic Melanoma

France
CHU de Reims

Unknown

Molecular Characterization of Primary Mucosal Melanoma (MELMUQ)

Mucosal Melanoma

France
University Hospital, Caen

Completed

Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination (O-Mel-Sora)

Uveal Melanoma

France
Assistance Publique Hopitaux De Marseille

Unknown

Study of Risk Factors and Clinical Characterization of Rapidly Growing Melanoma

Melanoma Cancer

France
Institut Curie

Unknown

Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye

Intraocular Melanoma

France
Institut Curie

Completed

Circulating Tumoral DNA in Choroidal Melanoma (ctDNA MU) (ctDNA MU)

Choroidal Melanoma

France
Centre Hospitalier Universitaire de Nice

Completed

Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes (EXOSOMES)

Metastatic Melanoma

France
Assistance Publique Hopitaux De Marseille

Completed

Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study

Metastatic Melanoma

France
Hospices Civils de Lyon

Completed

Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma (IMMUNONIVO)

Metastatic Melanoma

France
Hospices Civils de Lyon

Completed

Pre Transplantation Melanoma (MPG)

Malignant Melanoma

France
University Hospital, Montpellier
Saint-Louis Hospital, Paris, France

Completed

Tolerance of Targeted Therapy Used in Metastatic Melanoma in Patients Aged Over 65 and 75-year-old (TOLBRIPA)

Metastatic Melanoma

France
Institut Curie

Completed

Study of Circulating Tumoral DNA in Metastatic Choroidal Melanoma

Choroidal Melanoma, Diffuse

France
Centre Hospitalier Universitaire de Nice

Completed

Circulating Cell-free DNA in Metastatic Melanoma Patient: Mutational Analyses in Consecutive Measurement Before and After Chemotherapy (AMMAM)

Metastatic (Stage IV) Melanoma

France
Hospices Civils de Lyon

Unknown

Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies (PAIR)

Metastatic Melanoma

France
Centre Hospitalier Universitaire, Amiens

Unknown

New Tumor Models in Three Dimensions and in a Human Skin Environment for Personalized Melanoma Therapy (SkinTher)

Melanoma (Skin)

France
Centre Hospitalier Universitaire de Nice

Recruiting

Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 Therapy (TEP-ANTI-PD1)

Metastatic Melanoma

France
University Hospital, Strasbourg, France
Bristol-Myers Squibb

Completed

Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis (CRIRIN)

Melanoma (Skin)

France
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

France
Centre Hospitalier Universitaire de Nice

Recruiting

Study of Alterations in Tumor Metabolism Associated With the Development of Immunotherapy Resistance in Melanoma (MEL-META)

Melanoma (Skin)

France
University of California, Irvine
Pfizer

Completed

Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma

Melanoma | Malignant Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Gustave Roussy, Cancer Campus, Grand Paris

Terminated

Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma (Mel-Ipi-Rx)

Malignant Melanoma

France
Institut de Cancérologie de Lorraine

Completed

Therapeutic Drug Monitoring of BRAF-mutated Advanced Melanoma (OPTIMEL)

Melanoma (Skin)

France
University of California, Irvine
GlaxoSmithKline

Completed

Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma

Unresectable Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
Nantes University Hospital

Completed

Optimizing Access to Care Through New Technologies: a Randomized Study Evaluating the Impact of Telephone Contact and the Sending by the General Practitioner of Suspicious Lesions Melanoma Photographs Taken With a Smartphone, on the Time Limit to the Consultation With a Dermatologist (OASE Melanome)

Patients at Risk for Melanoma

France
Nantes University Hospital

Completed

COPARIME: Pilot Study of a Target Detection of Malignant Melanoma

Patients at Risk for Melanoma

France
Gustave Roussy, Cancer Campus, Grand Paris

Completed

A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma (NIVIPIT)

Stage III/IV Melanoma

France
Poitiers University Hospital

Completed

Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEK (SVALMEL)

Unresecable Stage IIIc or IV Melanoma

France
Institut du Cancer de Montpellier - Val d'Aurelle

Completed

Fotemustine in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

France
University Hospital, Brest

Recruiting

PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy (IMMUNOPET2)

Metastatic Melanoma

France
Centre Hospitalier Universitaire de Nice

Recruiting

Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors (mela-quantif)

Melanoma (Skin)

France
Azienda Ospedaliera di Perugia

Not yet recruiting

Impact of Anti PD-1 Therapy in Children, Adolescents and Young Adults (CAYA) Melanoma Patients (MELCAYA)

Advanced Melanoma | Early Melanoma

Italy, Sweden, France, Germany, Netherlands, Poland, Spain
Aduro Biotech, Inc.

Terminated

Safety of ADU-1604 in Adults With Metastatic Melanoma

Metastatic Melanoma

Spain, France
Assistance Publique - Hôpitaux de Paris

Unknown

Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma (OPTIMUM)

Melanoma BRAF V600E/K Mutated | CDNKN2A Loss Defined

France
Institut Curie

Unknown

Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma (imMUno)

Uveal Melanoma

France
Institut Curie
Genentech, Inc.

Completed

A Feasibility Study to Identify T-cell Responses to Neo-epitopes in Tumor Invaded Lymph Nodes (NeoEpitope)

Breast Cancer | Cutaneous Melanoma

France
Institut Curie

Active, not recruiting

Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser)

Uveal Melanoma | Melanoma, Uveal

France
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma (IMMUQ)

Head and Neck Mucosal Melanomas

France
Centre Oscar Lambret
Novartis; National Cancer Institute, France

Terminated

Imatinib in Adult Patients With Metastatic Ocular Melanoma (O-Mel-Inib)

Melanoma

France
Centre Antoine Lacassagne

Recruiting

18FDG PET for Early Identification of Tumor Exhaust for Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Bronchopulmonary Carcinoma or Melanoma (FDG-IMMUN)

Non-Small Cell Bronchopulmonary Carcinoma or Melanoma

France
University Hospital, Montpellier

Recruiting

Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis

Metastatic Melanoma

France
Institut Curie
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME) (PLUME)

Metastatic Uveal Melanoma

France
Assistance Publique - Hôpitaux de Paris

Completed

Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients (IMMUMELA)

Melanoma

France
Institut Curie

Recruiting

Early Integration of Supportive Care for Metastatic Uveal Melanoma Patients (EarlyTogether)

Uveal Melanoma

France
Institut Curie

Recruiting

Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME) (SALOME)

Uveal Melanoma

France
Institut Curie

Completed

Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)

Uveal Melanoma

France
Centre Hospitalier Universitaire de Nice

Recruiting

Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma (BMUMM)

Cutaneous Melanoma

France

3

Subscribe